Get an alert when REGENERON UK LIMITED files next

Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.

Free · confirmation link first · unsubscribe in one click

Next accounts due

2026-09-30 (in 4mo)

Last filed for 2024-12-31

Confirmation statement due

2027-02-28 (in 9mo)

Last made up 2026-02-14

Watchouts

None on the register

Cash

£30M

+19,159.1% vs 2023

Net assets

£19M

+57.1% vs 2023

Employees

268

+24.7% vs 2023

Profit before tax

£10M

+45.4% vs 2023

Accounts

2-year trend · latest reflected 2024-12-31

Metric Trend 2023-12-312024-12-31
Turnover £72,987,555£84,386,150
Operating profit £6,541,732£10,403,545
Profit before tax £6,649,371£9,667,549
Net profit £5,712,367£7,070,502
Cash £156,306£30,103,155
Total assets less current liabilities £12,385,094£19,455,596
Net assets £12,385,094£19,455,596
Equity £12,385,094£19,455,596
Average employees 215268
Wages £35,991,519£40,787,074

Values shown as filed in the company's annual accounts. indicates the figure wasn't present under that line item in that period. About these numbers

Ratios

Computed from the line items above — sparklines read oldest → newest

Ratio Trend 2023-12-312024-12-31
Operating margin 9.0%12.3%
Net margin 7.8%8.4%
Return on capital employed 52.8%53.5%
Gearing (liabilities / total assets) 76.4%76.1%
Current ratio 1.11x1.21x
Interest cover 28.86x7.95x

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Audit & accounting basis

Accounting basis
FRS 102
Reporting scope
Standalone (parent only)
Auditor
PricewaterhouseCoopers LLP
Audit opinion
Unqualified (clean)
Going concern
Affirmed

“These financial statements have been prepared on a going concern basis, which the Directors believe to be appropriate. The Company is funded through providing development services, including clinical development services, primarily in connection with the development of RIRE products and product candidates. Further, Regeneron, its ultimate parent, has provided a letter of support to ensure that the Company can meet its obligations for a period of at least twelve months from the issuance of these financial statements. Additionally, the Company does not currently have the intention nor the need to liquidate or cease its operations in the foreseeable future.”

Significant events

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

People

3 active · 7 resigned

Name Role Appointed Born Nationality
ACCOMPLISH SECRETARIES LIMITED Corporate Secretary 2017-03-31
BERKOVIC, Zoran Director 2018-05-16 Aug 1977 American
VOLPE, Mark Director 2016-10-19 Jul 1972 American
Show 7 resigned officers
Name Role Appointed Resigned
SKADDEN, ARPS, SLATE, MEAGHER & FLOM (CORPORATE SERVICES) LIMITED Corporate Secretary 2007-02-15 2017-03-31
SWIFT INCORPORATIONS LIMITED Corporate Nominee Secretary 2007-02-15 2007-02-15
FENIMORE, Christopher Robert Director 2014-07-18 2024-02-06
GOLDBERG, Murray. A Director 2007-02-15 2014-07-18
LANDRY, Jeffrey Director 2016-10-19 2018-05-16
MCCORKLE, Douglas Steven Director 2014-07-18 2016-10-12
SCHLEIFER, Leonard. S Director 2007-02-15 2014-07-18

Ownership

Persons with significant control

Name Kind Nature of control Notified Status
Regeneron Pharmaceuticals, Inc. Corporate entity Shares 75–100%, Voting 75–100%, Appoints directors 2016-04-06 Active

Filing timeline

Last 20 of 64 total filings

Date Type Category Description
2026-02-20 CS01 confirmation-statement Confirmation statement with no updates PDF
2025-09-12 AA accounts Accounts with accounts type full
2025-02-17 CS01 confirmation-statement Confirmation statement with updates PDF
2024-10-14 AA accounts Accounts with accounts type full
2024-02-26 CS01 confirmation-statement Confirmation statement with no updates PDF
2024-02-09 TM01 officers Termination director company with name termination date PDF
2023-12-13 CH01 officers Change person director company with change date PDF
2023-08-22 AA accounts Accounts with accounts type full
2023-02-14 CS01 confirmation-statement Confirmation statement with no updates PDF
2022-06-17 AA accounts Accounts with accounts type full
2022-02-21 CS01 confirmation-statement Confirmation statement with no updates PDF
2021-06-21 AA accounts Accounts with accounts type full
2021-02-17 CS01 confirmation-statement Confirmation statement with no updates PDF
2020-06-22 AA accounts Accounts with accounts type small
2020-02-18 CS01 confirmation-statement Confirmation statement with updates PDF
2020-02-18 CH01 officers Change person director company with change date PDF
2020-02-18 CH01 officers Change person director company with change date PDF
2020-02-18 CH01 officers Change person director company with change date PDF
2019-10-15 AD01 address Change registered office address company with date old address new address PDF
2019-08-28 AA accounts Accounts with accounts type small

Public-record activity

Raw counts from Companies House — last 12–24 months

Filings
2

last 12 months

Capital events
0

last 24 months

Officers appointed
0

last 12 months

Officers resigned
0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

Year-on-year

FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Official Companies House page